

North Central Cancer Treatment Group

N027D A Phase I Study of CCI-779 and Temozolomide in Combination with Radiation
Therapy in Glioblastoma Multiforme

Status Change – January 24, 2007

NOTICE OF STATUS CHANGE

This study has re-opened to accrual for 3 patients at dose level 2 effective
Wednesday, January 24, 2007.

Please retain this notice with the protocol.